• 沒有找到結果。

[PDF] Top 20 Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis

Has 10000 "Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis" found on our website. Below are the top 20 most common "Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis".

Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis

Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis

... Taiwanese patients was not available from medical chart ...effects with TB treatment ...function in most patients was performed on a regular biweekly or monthly ...recorded in ... See full document

21

Hepatitis B viral factors and treatment responses in chronic hepatitis B

Hepatitis B viral factors and treatment responses in chronic hepatitis B

... circle with angles equal to notch frequen- cies such that the frequency response of filter has zero gains at the notch ...circle and near zeros to the make frequency response of the non-notch band be a unit ... See full document

9

Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients

Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients

... CHC patients were enrolled from the gastroenterological clinics of the National Taiwan University Hospital and its Yun-Lin ...CHC patients were selected from a previous prospective study of factors ... See full document

9

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

... cirrhosis and hepatocellular carcinoma, even if the patients had low serum HBV DNA ...levels. In addition, the risk of accu- mulating accessory mutations may ...of patients and the ... See full document

7

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

... a viral acceleration model to explain the viral dynamics of patients with CHC receiving Peg-IFN plus ribavirin treatment under the assumption of target cells, T, remaining at their ... See full document

6

Predictive Value of Baseline and On-Treatment Quantitative Serum HBsAg Levels in Therapeutic Outcome to Entecavir in Patients with Chronic Hepatitis B

Predictive Value of Baseline and On-Treatment Quantitative Serum HBsAg Levels in Therapeutic Outcome to Entecavir in Patients with Chronic Hepatitis B

... Baseline and On-Treatment Quantitative Serum HBsAg Levels in Therapeutic Outcome to Entecavir in Patients with Chronic Hepatitis B Tsung-Yu Tsai, Cheng-Yuan Peng, ... See full document

2

Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B

Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B

... surrogate treatment for patients with a suboptimal response to LVD or ...reduce viral breakthrough in CHB ...three treatment groups, with the adherence rate of >90% during ... See full document

32

Predictive value of baseline and on-treatment quantitative serum HBsAg levels in therapeutic outcome to entecavir in patients with chronic hepatitis B.

Predictive value of baseline and on-treatment quantitative serum HBsAg levels in therapeutic outcome to entecavir in patients with chronic hepatitis B.

... Baseline and On-Treatment Quantitative Serum HBsAg Levels in Therapeutic Outcome to Entecavir in Patients with Chronic Hepatitis B Cheng-Yuan Peng, Hsueh-Chou Lai, ... See full document

1

Vitamins B status and anti-oxidative defense in patients with chronic hepatitis B or hepatitis C virus infection

Vitamins B status and anti-oxidative defense in patients with chronic hepatitis B or hepatitis C virus infection

... these patients, especially HCV patients, to obtain sufficient dietary B vitamins intake in order to maintain normal B vitamins associated physio- logical ...safe and could benefit infected ... See full document

10

Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B

Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B

... consistent with previous studies that have identified severity of hepatic dysfunction as the major outcome determinant in acute exacerbation of CHB 6, 7, 11-13, 22 ...INR, and MELD score were all ... See full document

25

Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

... to patients with a high viral load at baseline given that the average HBV DNA reduction with even the most potent NAs is only 6–7 log copies/mL in one year of ...oral treatment ... See full document

8

Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis B Viral Infection

Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis B Viral Infection

... effective and long-lasting treatment of morbidly obese ...safety and efficacy of bariatric surgery in patients with hepatitis B viral (HBV) infection is not ... See full document

1

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients

... these patients and should have a strict follow up of these ...to treatment-experienced patients in general remains to be ...positive patients received only 24 weeks of Peg-IFN ... See full document

28

Polyunsaturated fatty acids (PUFAs) levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection (HCV)

Polyunsaturated fatty acids (PUFAs) levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection (HCV)

... common in clinical practice and are similar to sickness behaviors due to inflammatory activation after cytokine administration in animals or ...mediate in somatic symptoms in depression ... See full document

1

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C

... those with HBV-associated HCC, 12 and HCV leads to liver cirrhosis more often than HBV, which may also indicate different hepatocarcinogenic mechanisms between HBV and ...of chronic HBV ... See full document

8

Treating Chronic Hepatitis C with Pegylated Interferon and Ribavirin Between the Incarcerated and
the Community Patients

Treating Chronic Hepatitis C with Pegylated Interferon and Ribavirin Between the Incarcerated and the Community Patients

... incarcerated patients received treatment in the past two years since 2013 while the community patients were treated from ...experienced in treating chronic hepatitis C ... See full document

8

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

... sustained viral eradication, instead of a transient ...to patients with serious comorbidity or hepatic ...response, viral genotype, viral load, life style, and over-the-counter ... See full document

28

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

... mutations in the precore or core promoter regions of the viral genome such that HBeAg is no longer expressed or is down-regulated, and it has been suggested that this gives the mutant an immunologic ... See full document

10

By observing different types of tongue diagnosis in relation to  different stages of viral hepatitis patients, and changes of heath  status and tongue diagnosis after the treatment of

By observing different types of tongue diagnosis in relation to different stages of viral hepatitis patients, and changes of heath status and tongue diagnosis after the treatment of

... diagnosis in traditional Chinese medicine. There were 86 hepatitis patients agreed to participate in the study while 4 of them withdrew earlier, ending with 82 remained in the ... See full document

1

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis

... SD and were compared with independent student ...(%) and were compared using chi-square or Fisher’s exact tests where ...analysis with log-rank test. The patients were censored when ... See full document

23

Show all 10000 documents...